SGMO vs PRME

For growth investors, Prime Medicine, Inc.

(PRME) is the stronger pick with 55. 3% revenue growth year-over-year, versus -67. 2% for Sangamo Therapeutics, Inc. (SGMO). Analysts rate Prime Medicine, Inc. (PRME) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Prime Medicine, Inc.

(PRME) delivered a total return of -79. 7%, compared to -99. 0% for Sangamo Therapeutics, Inc. (SGMO). Over 10 years, the gap is even starker: PRME returned -55. 5% versus SGMO's -98. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Sangamo Therapeutics, Inc.

(SGMO) is the lower-risk stock at 1. 65β versus Prime Medicine, Inc. 's 2. 26β — meaning PRME is approximately 37% more volatile than SGMO relative to the S&P 500. On balance sheet safety, Prime Medicine, Inc. (PRME) carries a lower debt/equity ratio of 96% versus 134% for Sangamo Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Prime Medicine, Inc.

(PRME) is pulling ahead at 55. 3% versus -67. 2% for Sangamo Therapeutics, Inc. (SGMO). On earnings-per-share growth, the picture is similar: Sangamo Therapeutics, Inc. grew EPS 66. 9% year-over-year, compared to 18. 3% for Prime Medicine, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Sangamo Therapeutics, Inc.

(SGMO) is the more profitable company, earning -169. 4% net margin versus -43. 4% for Prime Medicine, Inc. — meaning it keeps -169. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SGMO leads at -179. 9% versus -45. 0% for PRME. At the gross margin level — before operating expenses — SGMO leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Sangamo Therapeutics, Inc.

(SGMO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Prime Medicine, Inc. (PRME) carries a higher beta of 2. 26 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SGMO: -98. 4%, PRME: -55. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SGMO is a small-cap quality compounder stock; PRME is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.